Agilent Technologies Appoints Fred Strohmeier Agilent Senior VP And President Of Life Sciences And Diagnostics Group

Agilent Technologies Inc. (NYSE: A) today announced that Fred Strohmeier, vice president and general manager of Agilent’s Life Science Products and Solutions, has been named senior vice president, Agilent, and president of Agilent’s Life Sciences and Diagnostics Group (LDG), effective immediately.

Strohmeier has been in charge of Agilent’s life sciences business, the largest organization in the LDG business group. He was previously general manager of the Liquid Phase Analysis Division. As a 34-year veteran of the company, he has held positions in R&D, manufacturing and general management. He is based in Waldbronn, Germany.

“Fred is an excellent choice to lead this fast-growing business segment,” said William (Bill) Sullivan, Agilent president and CEO. “He is a highly respected leader with a wealth of deep experience and expertise in life sciences products and solutions—the foundation for LDG. Fred was an integral part of the formation of the new LDG, and I look forward to his leadership of the group.”

Lars Holmkvist, who previously headed LDG, has left the company for personal reasons.

About Fred Strohmeier

Fred Strohmeier was named senior vice president of Agilent and president of the newly formed Life Sciences and Diagnostics Group (LDG) in December 2013.

Strohmeier has been instrumental in the development of the life sciences business within Agilent, including most recently serving as vice president and general manager of the Life Science Products and Solutions business. This business became the foundation for the creation of LDG, the business group that Strohmeier now leads and was instrumental in forming.

Previously Strohmeier was vice president and general manager of the Liquid Phase Analysis Division, which includes liquid phase separations, software and informatics as well as automation solutions—all key elements of the complete workflow for life sciences labs.

A 34-year veteran of the company, Strohmeier is deeply steeped in all aspects of the business, including R&D, manufacturing and general management.

If you liked this article you might like

What a Difference a Day Makes for New SEC Rule

Jim Cramer: Agilent Technology Has Been One of My Favorites

Jim Cramer -- Agilent Is 'Continuing to Defy Gravity'

Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis